

Colorado Molecular Correlates Laboratory

Requisition Form
University of Colorado Denver - Anschutz Medical Campus 12705 E. Montview Blvd., Ste. 400, Aurora, CO 80045 Phone: 303-724-4754 Fax: 303-724-3096 CMOCO@ucdenver.edu



ORDERING PHYSICIAN/LABORATORY				PATIENT INFORMATION (please print)					
Physician's Name:				Name (Last, First)	:				
Practice Name:				Patient Address:					
Address:				City:			State:	Zip:	
City:	State:	Zip:		Phone Number:			Į		
Phone Number:	Fax Number:	1		Gender:	ıle 🗆 Male		Date of Birth:		
Physician's Signature (Required):	l .	Date:		Patient ID:					
□ Check here to allow us to modify the order based on sample quantity & quality. SPECIMEN INFORMATION									
Specimen type/collection procedure:				Place of Service a	t Time of Collection/C		ate of Collection:	: Date of IP Discharge:	
Materials Sent:				☐ IN-PATIEN Clinical History:	T OUT-PATIE	:N I		ICD-10 code(s):	
Specify Block(s) & Unstained/Stained Slides with their quantity and identifers									
TEST SELECTION									
Melanoma ^{1, 2}		Thyroid ^{1, 2}	120101			NGS	6 Mutation Te	sting (gene list)	
Cutaneous Mutations: BRAF, NRAS, KIT, MAP2	iated Thyroid Ca on: BRAF	ancer							
If negative for the above genes, reflex to: Fusions: BRAF, ALK, ROS1, NTRK1/2/3, RET Mutations: RAS				flex to:	ex to: NGS Fusion Testing (gene list) (all genes will be billed/charged)				
Uveal			ons: RET, NTRK: ic Thyroid Canc		'2/3, RET, PAX8-PPARg			Fusion Testing (gene list)	
Mutations: GNAQ, GNA11 Mutations: BRAF If negative for the above genes, reflex to: If negative for BRAF, re				flex to:	(all genes will be billed/charged) ex to:			- '	
				/2/3, RET, PAX8-PPARg					
Rapid BRAF reflex to panel Mutations: Rapid BRAF		Mutatio	y Thyroid Cance ons: RET						
If negative, will reflex to appropriate p	anel above	_	tive for RET, refle ations: RAS	ex to:					
Urothelial ^{1, 2} Mutations: FGFR2/3, PIK3CA, ERBB2		Add-on gen	e	_	_	_	_		
Breast 1, 2 Mutations: PIK3CA, ESR1, ERBB2		∐AKT1 □ALK	☐ CTNNB1 ☐ DDR2	□ FGFR3 □ FOXL2	∏ KDR ∏ KIT	☐ PIK3R ☐ POLE	_		
Endometrial ^{1, 2}			□ bbrz □ egfr	☐ FOXL2	□ KN □ KRAS	PTEN			
Mutations: POLE, CTNNB1, TP53		□aR	☐ ERBB2	☐ GNAQ	☐ MAP2K1				
Relatedness of multiple lesions		∐ <i>ATM</i> □ <i>AURKA</i>	☐ ERBB3	□GNAS □H3F3A	☐ MET ☐ MLH1	☐ RB1 ☐ RET			
(multiple primary vs. metastasis) Lesions to compare:		BRAF	\Box ESR1	☐ HNF1A	□ MLH 1 □ NOTCH1		☐ RET ☐ VHL ☐ RHOA		
		CDH1	☐ FBXW7	HRAS	□NRAS	ROS1			
		☐ CDK4 ☐ CDKN2A	\Box FGFR1 \Box FGFR2	□ IDH1 □ IDH2	☐ PDGFRA ☐ PIK3CA	☐ SMAD			
			□rgrkz		□ PIN3CA	□ SIVIAR	СВТ		
FISH ANALYSIS MUTATIONAL ANALYSIS (Targeted Assays)				MSI					
	RAF _ GFR	NRAS Microsatellite MGMT promoter							
	DH1/2	MLH1 promoter methylation							
HER2/neu (ERBB2)	RAS [TERT promote	er						
Please Obtain Pathology Materials from Outside Institution (Pathology Report Required, please attach pathology report or check here if available in UCH EMR)				Notes/Special Requests:					
Consultation and Report on Referred Slides and/or Materials (surgical pathology consultation for diagnosis)									
All tests include physician interpretation and report unless checked here; contact lab for service eligibility for									
technical only. The second of the									
other components of testing will not be cancelled unless otherwise specified. 2. Only indicated genes will be reported. Select 'add-on gene' if desired.									
Only indicated genes will be reported. Select	add-on gene' il	desired.							
		Note: For	any test not liste	d, please call for	availability.				

BILLING INFORMATION									
☐ Self-Pay ☐ Insurance	Insured's Relation to Patient: ☐ Self	Insurance (For non-University of Colorado Hospital patients, please see below):							
☐ Physician/Lab	Spouse	Insured's Name (if not patient):							
Grant	Dependent								
Claims Address:			City:		State:	Zip:			
Insurance ID#:			Group Name:		Group Number:				
Grant Info (Grant Name, Number, Study Coordinator, PI, and SpeedType):									
BILLING INFORMATION FOR PATIENTS OUTSIDE THE UNIVERSITY OF COLORADO HOSPITAL									
The CY 2018 OPPS/ASC final rule (82 FR 52533-52540) introduced a new exception to current laboratory DOS regulations at 42 CFR 414.510. The new exception permits independent laboratories to bill Medicare directly for molecular pathology tests (CPT codes 81105-81479), which are excluded from the OPPS packaging policy, if the specimen was collected from a hospital outpatient encounter. Payers following this rule include: Medicare, Medicare HMOs, VA and United Healthcare. No such rule has been implemented for specimens collected from hospital inpatients.									
IN-PATIENT STATUS AT TIME OF COLLECTION AND/OR ORDER									
ORDERED WITHIN 14-DAYS FROM THE DATE OF DISCHARGE: The technical component of any/all services will be billed back to your institution (please provide BILL TO INFORMATION below). The professional interpretation will be billed to insurance.									
ORDERED 14-DAYS AFTER THE DATE OF DISCHARGE: Any/All services will be billed to insurance.									
		OUT-PATIENT STATUS AT TIME							
ORDERED WITHIN 14-DAYS FROM THE DATE OF COLLECTION: The technical components of microdissection (88381), FISH (88271-88275) and IHC (88341-88342, 88360-88361) will be billed back to your institution (please provide BILL TO INFORMATION below). The professional interpretation will be billed to insurance.									
ORDERED 14-DAYS AFTER THE DATE OF COLLECTION: Any/All services will be billed to insurance.									
TECHNICAL COMPONENT - BILL TO INFORMATION									
Institution Name:			Billing Person Name:						
Address:									
City:			State:	Zip:					
Phone:			Fax:	-					
Billing Person E-mail:									